| CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma MHM Diekstra, JJ Swen, E Boven, D Castellano, H Gelderblom, ... European urology 68 (4), 621-629, 2015 | 99 | 2015 |
| Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662 MHM Diekstra, HJ Klümpen, M Lolkema, H Yu, JSL Kloth, H Gelderblom, ... Clinical Pharmacology & Therapeutics 96 (1), 81-89, 2014 | 90 | 2014 |
| Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma MHM Diekstra, X Liu, JJ Swen, E Boven, D Castellano, H Gelderblom, ... European journal of clinical pharmacology 71, 1477-1484, 2015 | 30 | 2015 |
| Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma MH Diekstra, A Belaustegui, JJ Swen, E Boven, D Castellano, ... The Pharmacogenomics Journal 17 (1), 42-46, 2017 | 28 | 2017 |
| Population modeling integrating pharmacokinetics, pharmacodynamics, pharmacogenetics, and clinical outcome in patients with sunitinib‐treated cancer MH Diekstra, A Fritsch, F Kanefendt, JJ Swen, DJAR Moes, F Sörgel, ... CPT: pharmacometrics & systems pharmacology 6 (9), 604-613, 2017 | 27 | 2017 |
| A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review MHM Diekstra, JJ Swen, H Gelderblom, HJ Guchelaar Expert Review of Molecular Diagnostics 16 (5), 605-618, 2016 | 25 | 2016 |
| Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer—GEnetic-and tumor-related biomarkers for response and toxicity LFM van der Zanden, SH Vermeulen, A Oskarsdottir, JSF Maurits, ... Urologic Oncology: Seminars and Original Investigations 35 (8), 529. e9-529. e16, 2017 | 18 | 2017 |
| A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma X Liu, JJ Swen, MHM Diekstra, E Boven, D Castellano, H Gelderblom, ... Clinical Cancer Research 24 (10), 2350-2356, 2018 | 11 | 2018 |
| Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma M Apellániz-Ruiz, MH Diekstra, JM Roldán, E Boven, D Castellano, ... Pharmacogenetics and Genomics 27 (6), 227-231, 2017 | 9 | 2017 |
| Practical recommendations for the manipulation of kinase inhibitor formulations to age-appropriate dosage forms EC Bernsen, VJ Hogenes, B Nuijen, LM Hanff, ADR Huitema, ... Pharmaceutics 14 (12), 2834, 2022 | 5 | 2022 |
| Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib MHM Diekstra, JJ Swen, LFM van der Zanden, SH Vermeulen, E Boven, ... Cancers 14 (2838), 1-15, 2022 | 3 | 2022 |
| Comments on ‘A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation’ MHM Diekstra, R Malmberg, S Sleijfer, RWF van Leeuwen European Journal of Cancer 138, 54-56, 2020 | 3 | 2020 |
| Genetic variants found in paediatric oncology patients with severe chemotherapy-induced toxicity: A case series EC Bernsen, LM Hanff, LM Haveman, BBJ Tops, M van der Lee, JJ Swen, ... Journal of Oncology Pharmacy Practice 29 (5), 1237-1245, 2023 | 1 | 2023 |
| What do we need to make genetic biomarker-guided treatment for renal cell carcinoma a reality? MH Diekstra, X Liu, JJ Swen, HJ Guchelaar Pharmacogenomics 18 (1), 1-4, 2017 | 1 | 2017 |
| De noodzaak voor hogere propofoldoseringen na herhaalde sedaties voor invasieve procedures bij kinderen met acute lymfatische leukemie–een zorgevaluatie: een retrospectieve … J Graafsma, E Heeremans, M Diekstra, C Schuiling-Veninga, L Hanff Pharmaceutisch Weekblad 158 (44), 19-26, 2023 | | 2023 |
| Tolerance to propofol in children with acute lymphoid leukemia when undergoing repeated sedations for invasive procedures: a clinical care evaluation J Graafsma, EH Heeremans, M Diekstra, CCM Schuiling-Veninga, L Hanff | | 2022 |
| Swen MHM Diekstra Zanden, LFM an der, Vermeulen, SH, Mathi ssen, R. H.., Fukunaga, K …, 2022 | | 2022 |
| Logical Imputation to Optimize Prognostic Risk Classification in Metastatic Renal Cell Cancer JSF Maurits, LFM Van Der Zanden, MHM Diekstra, V Ambert, ... Kidney Cancer 6 (3), 169-178, 2022 | | 2022 |
| 685P Genome-wide association meta-analysis identifies novel variants that correlate with efficacy outcomes in sunitinib-treated patients with metastatic renal cell carcinoma M Diekstra, J Swen, L van der Zanden, S Vermeulen, E Boven, ... Annals of Oncology 32, S703-S704, 2021 | | 2021 |
| Farmacogenetica mogelijk zinvol bij gebruik sunitinib: CYP3A5-en ABCB1-varianten voorspellen effect behandeling MHM Diekstra, HJ Guchelaar, JJ Swen, H Gelderblom Pharmaceutisch Weekblad 153 (7), 20-21, 2018 | | 2018 |
